Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00576
|
|||||
| Drug Name |
Telithromycin
|
|||||
| Synonyms |
(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A; HMR 3647; HMR-3647; HMR3647; Ketek; Ketek (TN); Levviax; RU 66647; RU-66647; RU66647; TEL; Telithromycin (JAN/USAN/INN); Telithromycin [USAN:BAN:INN]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Community acquired pneumonia [ICD11: CA40] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C43H65N5O10
|
|||||
| Canonical SMILES |
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
|
|||||
| InChI |
InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
|
|||||
| InChIKey |
LJVAJPDWBABPEJ-PNUFFHFMSA-N
|
|||||
| CAS Number |
CAS 191114-48-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 812 | Topological Polar Surface Area | 172 | ||
| Heavy Atom Count | 58 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 13 | |||
| XLogP |
4.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103323138
, 111611540
, 12015022
, 124766275
, 126669903
, 134224303
, 135253289
, 135692562
, 139962352
, 140277637
, 141465063
, 144205007
, 144205756
, 14767066
, 14913885
, 152198790
, 160857220
, 164765238
, 17181612
, 175268627
, 179150119
, 210279153
, 210281475
, 223393880
, 226396929
, 247267318
, 252401574
, 34667812
, 57410165
, 633047
, 79644204
|
|||||
| ChEBI ID |
CHEBI:29688
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Gadobenate dimeglumine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7. | |||||
| 3 | Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.